Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

MLA

Ndashimye, Emmanuel, et al. “Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.” AIDS Research & Human Retroviruses, vol. 34, no. 5, May 2018, pp. 404–14. EBSCOhost, https://doi.org/10.1089/aid.2017.0205.

APA

Ndashimye, E., Avino, M., Kyeyune, F., Nankya, I., Gibson, R. M., Nabulime, E., Poon, A. F. Y., Kityo, C., Mugyenyi, P., Quiñones-Mateu, M. E., & Arts, E. J. (2018). Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. AIDS Research & Human Retroviruses, 34(5), 404–414. https://doi.org/10.1089/aid.2017.0205

Chicago

Ndashimye, Emmanuel, Mariano Avino, Fred Kyeyune, Immaculate Nankya, Richard M. Gibson, Eva Nabulime, Art F.Y. Poon, et al. 2018. “Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.” AIDS Research & Human Retroviruses 34 (5): 404–14. doi:10.1089/aid.2017.0205.